Atlas Trials

Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma

Clinical trial NCT04537442 · UNKNOWN

Trial details

NCT number
NCT04537442
Sponsor
Beijing Immunochina Medical Science & Technology Co., Ltd.
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2020-09-03
Primary completion
2022-12-30
Enrollment
10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.